Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Repare Therapeutics Inc is a precision oncology company engaged in the discovery and development of novel therapeutics. The company use its proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability,... Repare Therapeutics Inc is a precision oncology company engaged in the discovery and development of novel therapeutics. The company use its proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Using its SNIPRx platform, it is developing pipeline of SL product candidates, including its product candidate, RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. Mehr anzeigen
Realigning resources to extend runway to mid-2027 Focus on clinical development of RP-1664 (PLK4 inhibitor) and RP-3467 (Polθ ATPase inhibitor), with initial clinical readouts expected beginning...
Heavily-pretreated patients on lunresertib and camonsertib combination achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer Nearly half...
Event to be webcast live on Thursday, December 12 at 4:30 p.m. ET Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today...
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced a Cooperative Research and Development Agreement (CRADA...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.06 | -4.61538461538 | 1.3 | 1.36 | 1.22 | 266169 | 1.26365081 | CS |
| 4 | -0.12 | -8.82352941176 | 1.36 | 1.48 | 1.2 | 520034 | 1.32084419 | CS |
| 12 | -2.35 | -65.4596100279 | 3.59 | 4.0695 | 1.2 | 451693 | 1.98946899 | CS |
| 26 | -2.73 | -68.765743073 | 3.97 | 4.22 | 1.2 | 253697 | 2.28769351 | CS |
| 52 | -4.94 | -79.9352750809 | 6.18 | 8.49 | 1.2 | 223920 | 3.21148316 | CS |
| 156 | -12.15 | -90.7393577296 | 13.39 | 18.68 | 1.2 | 250513 | 8.8446677 | CS |
| 260 | -30.81 | -96.1310452418 | 32.05 | 46.44 | 1.2 | 216599 | 13.81258274 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
